Nicox SA

FinLantern in collaboration with Westmount Capital would like to invite you to a presentation by Nicox S.A., which is an international Ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Nicox is headquartered in Sophia Antipolis (Nice area, France) and is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX). 

Nicox was founded in 1996 around its proprietary nitric oxide-donating research platform.

Nitric oxide is an endogenous cell-signalling molecule of fundamental importance in physiology, and Nicox has developed a world-leading position in the discovery, synthesis and evaluation of nitric oxide-donating compounds for therapeutic use.  A significant proportion of its compounds have been developed through alliances with leading international pharmaceutical companies including Pfizer, AstraZeneca and Bausch + Lomb.

With 25,004,543 shares outstanding, has a market cap of 180.8 million (COX closed @ 7.81 on Tuesday Nov. 8th).

For further information, please consult Nicox web site


This presentation will take place as follows:

Date:          Thursday, November 24th, 2016.

Venue:       Grand Café al Porto (via Pessina 3 – Lugano)

Time:        12:00 – 12:15 Arrival of Participants & Aperitivo.

                   12:15 – 13:30 Luncheon & Presentation

                   13:45 – Conclusion. 

Speaker:  Michele Garufi, Co-Founder, Chairman &  Chief Executive Officer of the Company


Mr. Michele Garufi – Mr. Garufi, born in 1954 in Milano, Italy, graduated with full honors in Pharmaceutical Chemistry from the University of Milan in 1977. He obtained as well the Pharmacist Degree in 1989.
Mr. Garufi has extensive experience in business development, licensing and international marketing in the European pharmaceutical industry.
Before 1996, he was Vice President of the International Division and Director of Licensing at Recordati Italy and Managing Director of Recordati’s subsidiary in Spain. He previously served as Director, International Division at Italfarmaco (1988-1992), Assistant to the General Manager at Poli Chimica (1984-1988), Assistant to the President at Medea Research (1983) and Technical Director of one of the Italian subsidiaries of the Lipha Group (1978-1982).
In his carreer he also served as Board member for Novuspharma Srl, Novexel SA, Lica SA and he was co-founder and Board member of Scharper SpA.
In addition, Mr Garufi is co-founder of Delife Srl, an Italian dermatological Company.